| Date Filed | Type | Description |
| 10/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Notice of Delisting or Failure to... |
| 10/05/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 05/25/2023 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
| 05/23/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/13/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/13/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/06/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 03/31/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
8-K
| Quarterly results |
| 03/03/2023 |
SC 13G/A
| VICTORY CAPITAL MANAGEMENT INC reports a 3.9% stake in Equillium, Inc. |
| 01/31/2023 |
SC 13G/A
| VICTORY CAPITAL MANAGEMENT INC reports a 12.2% stake in Equillium, Inc. |
| 01/06/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 01/06/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 12/23/2022 |
8-K
| Termination of a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial ... |
| 12/14/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/14/2022 |
8-K
| Quarterly results |
| 12/06/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/06/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/06/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 10/26/2022 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 09/28/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 09/27/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 09/27/2022 |
8-K
| Investor presentation |
| 09/26/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 09/26/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Consent of Ernst & Young LLP, independent registered public accounting firm",
"Audited consolidated financial statements of Metacrine and its subsidiary as of and for the years ended December 31, 2021 and 2020, and the unaudited interim financial statements of Metacrine and its subsidiary as of June 30, 2022 and for the six months ended June 30, 2022 and 2021",
"Unaudited pro forma condensed combined balance sheet for the Company and its subsidiaries and Metacrine and its subsidiary as of June 30, 2022 and unaudited pro forma condensed combined statements of operations and comprehensive loss for the Company and its subsidiaries and Metacrine and its subsidiary for the year ended December 31, 2021 and for the six months ended June 30, 2022",
"Updated Equillium disclosure" |
|
|